CytomX Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 09/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $76.2 | $138.1 | $101.2 | $53.2 | — |
| Operating income | -$22.4 | $25.0 | -$6.5 | -$101.3 | — |
| Net income | -$17.4 | $31.9 | -$0.6 | -$99.3 | — |
| Cash Flow Statement | |||||
| Free cash flow | -$75.8 | -$86.5 | -$56.9 | -$112.5 | — |
Shares outstanding 217.7M · Free float 98.9%
Annual filing data through FY ended December 31, 2025; float as of August 31, 2026.